API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
HMPL-523 (sovleplenib) is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. It is being evaluated for the treatment of warm antibody autoimmune hemolytic anemia.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
HMPL-523 (sovleplenib) is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (Syk). It is being developed in phase 3 clinical trials for the treatment of hematological malignancies and immune diseases.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
HMPL-523 (sovleplenib) is a novel, selective, oral inhibitor targeting spleen tyrosine kinase, which is investigated for the treatment of Thrombocytopenia and Hutchmed plans to submit the New Drug Application around the end of 2023.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
HMPL-523 (Sovleplenib) is an investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Sovleplenib is novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase, for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
HMPL-523 is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase, also known as Syk. The ESLIM-01 Phase III trial is underway to evaluate the efficacy and safety of HMPL-523 in treating patients with primary ITP.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
HMPL-523 is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase, also known as Syk. Also, Phase III study is based on encouraging data from the Phase Ib study of HMPL-523 in adult patients with ITP.
Lead Product(s): Sovleplenib
Therapeutic Area: Immunology Product Name: HMPL-523
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021